Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

PerkinElmer to Host Revolutionaries for Global Health Summit

Published: Wednesday, May 01, 2013
Last Updated: Wednesday, May 01, 2013
Bookmark and Share
Company to assemble thought leaders to share pioneering personalized health research and innovations.

PerkinElmer Inc. is hosting a Revolutionaries for Global Health Summit from Wednesday May 8th through Thursday May 9th 2013 at the Boston Marriot Newton Hotel. The Summit is a forum for leading researchers and physicians to network and share best practices in both science and business and participate in cutting-edge discussions to help lead to better prevention, detection and treatment of disease. The meeting program will feature world-renowned experts presenting key insights on finding, understanding, and acting upon the causes and effects of disease including cancer, diabetes and heart disease.

“From Cradle to Grave, Health is Personal.”

"The Revolutionaries for Global Health Summit is a unique forum that fosters collaboration and shares research on how to use disruptive technologies to enable the advancement of human health. Recognized scientific leaders from biotech, pharma and academia will discuss their strategies and insights on how to enable better approaches for disease prevention, diagnosis and screening regimens, creating safer and more effective personalized therapeutics," said Kevin Hrusovsky, President, Life Sciences & Technology, PerkinElmer. “Once again, we look forward to bringing together hundreds of scientists from throughout leading research institutions around the world to the Boston area to share valuable insights and spark innovative discussions.”

The Summit will feature notable keynote presentations:
•    A presentation titled, “Quantitative Human Phenotyping: The Next Frontier,” will be given by Dennis A. Ausiello, MD, Physician-in-Chief at Massachusetts General Hospital.
•    Charles Mattocks, host of the TV Show “The Poor Chef”, will be sharing insights on a new movement called The Diabetic You, and how lifestyle and eating choices can complement modern medicine. In addition, he will be overseeing the preparation of all the food at the event to make sure that is not only delicious, but also healthy.
•    Dr. Richard Baum, Chairman and Clinical Director of THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, will present “Personalized Molecular Targeted Radiotherapy of Cancer.”
•    Kevin Hrusovsky will present, “From Cradle to Grave, Health is Personal.” In the past year, PerkinElmer has made tremendous progress in the fight against cancer and disease. This talk will focus on how technology has contributed to this progress.

Attendees will have the opportunity to participate in six informative tracks in the following areas: next generation sequencing, in vivo imaging, targeted small molecule discovery, proteins and biologics, tissue and cellular imaging/molecular pathology and enabling and accelerating science through laboratory services and informatics.

In support of PerkinElmer’s vision of preventing disease, the American Cancer Society will be at the summit sharing information and recruiting volunteers for their cancer prevention study.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PerkinElmer, Sofie Biosciences Announce Benchtop PET Imaging Partnership
Preclinical PET imaging instruments in benchtop format help support high performance disease research, drug discovery and clinical translational applications.
Tuesday, June 10, 2014
Good Start Genetics, PerkinElmer Collaboration Expands Access to Genetic Carrier Screening Tests
Strategic agreement will broaden access to GoodStart Select™ tests to include obstetrics and gynecology and maternal fetal medicine physicians.
Monday, March 17, 2014
PerkinElmer Expands Reagent Portfolio for Faster Identification of Epigenetic Drug Candidates
The company announced the launch of four new cellular assay kits to help identify and characterize possible drug candidates targeting epigenetic enzymes related to key disease states.
Tuesday, February 07, 2012
Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!